Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Apr 18, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how effective drug treatments before and after surgery are for patients with locally advanced gastric cancer, specifically focusing on the tumor microenvironment (TME). The TME refers to the environment around the tumor, which can influence how well treatments work. Researchers want to see if a specific scoring system, called the TMEscore, can help predict which patients will benefit the most from these treatments. By understanding the relationship between the TME and treatment outcomes, the goal is to create a better system for evaluating how well these therapies work.

To participate in the trial, individuals must be between 18 and 75 years old and have a confirmed diagnosis of locally advanced gastric or gastroesophageal junction adenocarcinoma that is resectable, meaning it can be surgically removed. Participants will be asked to provide tumor tissue samples and must agree to receive drug therapy before and after surgery. Those with certain health conditions or who are pregnant or breastfeeding will not be eligible. If you join the study, you can expect to contribute to important research that could improve treatment options for gastric cancer patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically or cytologically confirmed locally advanced resectable gastric and gastro-oesophageal junction adenocarcinoma at the stage of cT2-T4aNxM0 (AJCC 8th) without distant metastases and without infiltration of adjacent structures and organs.
• • 2. 18-75 years old.
• • 3. Willing to provide residual tumor tissues after routine clinical diagnosis for tumor microenvironment detection analysis.
• • 4. Patients agree to participate in the study and sign the informed consent.
• • 5. Patients need to receive perioperative drug therapy.
• • 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
• Exclusion Criteria:
• • 1. Human epidermal growth factor receptor 2 (HER2) is positive, that is, tissue immunohistochemical staining (IHC) (3+) or IHC (2+), and tissue fluorescence in situ hybridization (FISH) is positive.
• • 2. Patients with major cardiovascular and cerebrovascular diseases (such as congestive heart failure, unstable heart colic, atrial fibrillation, stroke, transient ischemic attack, etc.).
• • 3. Allergies or contraindications to common chemotherapy drugs, immunotherapy drugs or the ingredients.
• • 4. Women who are pregnant, breast-feeding.
• • 5. Other conditions the investigator believes that it is not suitable to participate in this study.